Addex Therapeutics Ltd.: Form 20-F for the period ended Dec 31, 2019
Filed with the SEC on Apr 27, 2020 and accepted by EDGAR at Apr 24, 2020, 21:19 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2019-01-01 to 2019-12-31 | CHF 2.8m | ifrs-full:RevenueFromContractsWithCustomers |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −CHF 14.6m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months2019-01-01 to 2019-12-31 | −CHF 14.8m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | −CHF 9.5m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | CHF 28.5k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2019-12-31 | CHF 31.5m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2019-12-31 | CHF 32.4m | ifrs-full:CurrentAssets |
| Total assets | At period end2019-12-31 | CHF 33.0m | ifrs-full:Assets |
| Current liabilities | At period end2019-12-31 | CHF 5.7m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | At period end2019-12-31 | CHF 25.5m | ifrs-full:Equity |
| Shares outstanding | At period end2019-12-31 | 32,848,635 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001047469-20-002580. Last ingested by Listed: Oct 29, 2026, 06:06 ET. Listed shows no prices and gives no investment advice.